A New Face of Fibrin-Associated Large B-Cell Lymphoma: Epstein–Barr Virus-Positive Breast Implant-Associated Diffuse Large B-Cell Lymphoma
Jose Manuel Martin de Bustamante, Ana Mendoza, Samuel López‐Muñoz, Eugenia García‐Fernández, Pilar Gómez‐Prieto, Víctor Jiménez‐Yuste
Abstract
Recently, there have been reports of what could be a new lymphoproliferative entity: breast implant-associated Epstein-Barr virus positive (EBV+) diffuse large B-cell lymphoma (EBV+ BIA-DLBCL). The new World Health Organization classification has categorized it as fibrin-associated large B-cell lymphomas (FA-LBCLs); therefore, it could be referred to as breast implant-associated fibrin-associated large B-cell lymphomas (BIA-FA-LBCLs). Although the association between breast implants and lymphomas has been known since the mid-1990s, it has been almost exclusively breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Here, we describe the first case of BIA-FA-LBCL at our center, with a literature review of the clinical features, diagnosis and treatment approach of this lymphoma. We also explore the differential diagnosis of BIA-FA-LBCL, highlighting the diagnostic challenges and the reasons that have led these lymphomas to being labeled as a new face of FA-LBCL.